Enlivex Therapeutics (ENLV) Projected to Post Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to be releasing its Q1 2025 results before the market opens on Friday, December 5th. Analysts expect Enlivex Therapeutics to post earnings of ($0.12) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2025 earningreport for the latest details on the call scheduled for Thursday, December 4, 2025 at 5:00 PM ET.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV opened at $0.90 on Friday. Enlivex Therapeutics has a 52-week low of $0.83 and a 52-week high of $2.10. The firm has a market capitalization of $21.86 million, a price-to-earnings ratio of -1.55 and a beta of 1.20. The stock has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.11.

Analysts Set New Price Targets

Several brokerages have weighed in on ENLV. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enlivex Therapeutics in a report on Tuesday, November 11th. D Boral Capital lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday. Wall Street Zen raised shares of Enlivex Therapeutics to a “sell” rating in a research report on Saturday, August 30th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Enlivex Therapeutics in a report on Tuesday, September 2nd. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Susquehanna International Group LLP bought a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 54,850 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.23% of Enlivex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.